| An orally active farnesyltransferase inhibitor being developed by Eiger BioPharmaceuticals under license from Merck & Co. for the treatment of progeria and progeroid laminopathies. |
| Received its first approval on 20 November 2020 in the USA. |
| Approved to reduce the risk of mortality in HGPS and for the treatment of processing-deficient progeroid laminopathies in patients ≥ 12 months of age with a BSA of ≥ 0.39 m2. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.